Abstract Library

#4617 Analysis of new immunohistochemical biomarkers in a cohort of pancreatic NETs

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are rare diseases with a 10-year survival rate of only 40-50%. The ATRX, DAXX and ARX, PDX1 expressions in PanNETs were considered poor prognostic factors in some studies, but inconsistent in others.

Conference:

Presenting Author:

Authors: Ciobanu O, Martin S, Herlea V, Vasilescu F, Balaban D,

Keywords: Pancreatic neuroendocrine tumour, ATRX, DAXX, ARX, PDX1,

#4172 Hormonally characterised NF-PanNETs and their clinicopathological features

Introduction: PanNETs show pronounced hormonal heterogeneity. The expression of certain hormones may associate with functional syndromes, but also with histological and genetic features. However, detailed studies of hormonal patterns in PanNETs correlated to morphological and clinical data are lacking.

Conference:

Presenting Author: Moser E

Authors: Moser E, Ito A, Vogel L, Steiger K, Scheidhauer K,

Keywords: Neuroendocrine Tumor, hormonal expression, subtypes, outcome, transcriptional factors,

#4027 Prognostic impact of molecular signatures in pancreatic metastatic neuroendocrine tumors (PRODETEN)

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are an heterogenous group of tumors. This heterogeneity is not explained by the main known prognostic factors (extension, evolution slope and Ki67 index). New molecular biomarkers (ARX, ATRX, DAXX, menin, PDX1) seem promising in non-metastatic PNENs.

Conference:

Presenting Author: de Mestier L

Authors: Pokossy Epee J, Cros J, Cadiot G, Do Cao C, Hautefeuille V,

Keywords: pancreas, neuroendocrine, prognostic, ATRX, daxx, arx, pdx1, Super Learner, menin, biomarker,

#3476 A phase II single arm trial evaluating the efficacy and safety of Temozolomide for second-line treatment of neuroendocrine carcinomas progressing after first-line platinum-based therapy

Introduction: Second-line treatment for neuroendocrine carcinoma (NEC) have been investigated in prospective trials, with only few prospective trials ongoing. Therefore, there is no consensus on the second-line regimen to use in patients with progressive NEC. These patients have generally a poor performance status (PS) and the tolerance to combination therapy is low. Metronomic temozolomide showed, in retrospective trials, a good safety and efficacy profile.

Conference:

Presenting Author:

Authors: Cannella L, von Arx C, Bracigliano A, Pizzolorusso A, Antonella D,

Keywords: neuroendocrine, temozolomide, NEC, Treatment,

#972 Anti-Tumor Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to Ki-67 Score: A Multicentric Study From ELIOS (Educational Learning Investigational Observational Study)

Introduction: SSAs have been demonstrated to have antiproliferative effects in ileal NETs. The 2010 WHO NET classification provides a grading score which can be helpful in predicting tumor response to SSA.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Faggiano A

Authors: Faggiano A, Carratù A, Tafuto S, Lastoria S, Von Arx C,

Keywords: NET, SSA, G1, G2, WHO classification,